Hyqvia Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of intravenous ig therapy, high infection risk in pi patients, early adoption of sc immunoglobulins, need for improved quality of life, growth in immunology specialty care.

The growth in the forecast period can be attributed to rising diagnosis of primary immunodeficiency, expansion of home healthcare services, increasing pediatric pi management, preference for long interval dosing, growth in specialty pharmacy distribution. Major trends in the forecast period include shift toward less frequent immunoglobulin infusions, growing adoption of home based infusion therapies, rising demand for combination immunotherapy products, improved patient convenience in pi treatment, expansion of subcutaneous immunoglobulin use.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the hyqvia market. Autoimmune diseases are conditions where the immune system mistakenly attacks healthy cells, tissues, or organs, causing inflammation and dysfunction. These diseases are becoming more common due to factors such as genetic predisposition, environmental triggers, dietary changes, increased exposure to pollutants, and advancements in diagnostic capabilities. Hyqvia is used to treat autoimmune diseases by delivering immunoglobulin therapy, which helps modulate the immune system and reduce abnormal immune responses that target the body’s own tissues. For example, in May 2023, the NIHR Imperial Biomedical Research Centre, a UK-based government research institute, analyzed anonymized electronic health records from 22 million UK individuals to study 19 common autoimmune diseases, which affect around 10% of the population - 13% of women and 7% of men. As a result, the growing prevalence of autoimmune diseases is contributing to the expansion of the hyqvia market.

The increasing healthcare investment is expected to further drive the growth of the hyqvia market. Healthcare investment refers to the financial resources allocated to healthcare-related businesses, technologies, research, and infrastructure aimed at improving patient outcomes, supporting innovation, and driving industry growth. This investment is rising due to increasing demand for advanced medical treatments, technological innovations, an aging population, and a growing focus on improving global healthcare access and outcomes. Healthcare investment positively impacts HYQVIA by supporting its continued development, regulatory approvals, and broader access, ultimately driving its adoption for treating immunodeficiency and CIDP. For example, in April 2025, the American Medical Association, a US-based non-profit organization, reported that U.S. health spending rose by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, reflecting a significant acceleration compared to the 4.6% increase recorded in 2022. As a result, the growing healthcare investment is propelling the hyqvia market.

A key trend in the hyqvia market is the focus on developing innovative products, such as immune globulin infusion, to treat chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI). Immune globulin infusion involves administering antibody-rich plasma proteins to address immune deficiencies and autoimmune disorders. For example, in January 2024, Takeda Pharmaceutical Company Ltd., a Japan-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its product, HYQVIA® (immune globulin infusion 10% [human] with recombinant human hyaluronidase), for use as a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This FDA approval allows HYQVIA to be used to prevent relapses of neuromuscular disability and impairment caused by CIDP, a rare neuromuscular disorder that affects approximately five to seven individuals per 100,000 in the U.S.

Major companies operating in the hyqvia market are Takeda Pharmaceutical Company Limited.

North America was the largest region in the hyqvia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the hyqvia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyqvia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the hyqvia market by increasing costs related to human plasma sourcing, recombinant hyaluronidase production, and temperature controlled logistics. These impacts are more pronounced in regions heavily dependent on plasma imports such as asia pacific and latin america. Higher costs may influence reimbursement and therapy adoption rates. At the same time, tariffs are promoting regional plasma fractionation and strengthening domestic biologics manufacturing infrastructure.

The hyqvia market research report is one of a series of new reports that provides hyqvia market statistics, including hyqvia industry global market size, regional shares, competitors with a hyqvia market share, detailed hyqvia market segments, market trends and opportunities, and any further data you may need to thrive in the hyqvia industry. This hyqvia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hyqvia is a combination therapy used for primary immunodeficiency (PI) in both adults and children, consisting of human immune globulin (IgG) to provide essential antibodies and recombinant human hyaluronidase (rHuPH20) to enhance absorption under the skin. Administered subcutaneously once every three to four weeks, it enables larger, less frequent infusions at a single site, offering improved patient convenience compared to traditional therapies. Hyqvia helps reduce infection risk in individuals with low IgG levels due to PI, with common side effects including injection site reactions, headache, and flu-like symptoms.

The primary patient demographics for Hyqvia include pediatric and adult patients. Pediatric patients are individuals under the age of 18 who require specialized care for growth and development. Hyqvia is distributed through various channels, including hospitals, specialty pharmacies, home healthcare providers, and retail pharmacies, and is used for treating primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and other indications.

The hyqvia market consists of sales of hematology medications, gastrointestinal medications, vaccines, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.